By Fineline Cube Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with the Experimental Drug Development Centre (EDDC) of Singapore. The aim is to provide new drug candidates for lung cancer precision treatment, driven by a research and development model integrating artificial intelligence (AI), automation experimentation, and expert expertise. No financial details were disclosed.
Lung Cancer and Market Context
Lung cancer, the second most common cancer in the world, is the main cause of cancer death. According to relevant research reports, the global market size of NSCLC therapy is expected to exceed USD 20 billion by 2027. This partnership positions XtalPi and EDDC to address significant unmet medical needs in lung cancer treatment.
Research and Development Model
XtalPi will utilize its “intelligent automated drug research and development system” to generate and screen millions of molecules at the drug design stage, predicting the most promising drug molecules. Through the validation of the automated laboratory, rapid iterative optimization will be carried out, yielding more ideal pre-clinical candidate compounds (PCCs). Meanwhile, EDDC will provide valuable insights and research data on new NSCLC targets, with the overall goal of accelerating the drug discovery process and achieving clinical milestones.
Future Prospects and Strategic Implications
This collaboration underscores XtalPi’s commitment to leveraging AI and automation to advance drug discovery. By partnering with EDDC, XtalPi aims to accelerate the development of new treatments for non-small cell lung cancer, improving patient outcomes and contributing to the global fight against cancer.-Fineline Info & Tech